Press coverage about Gemphire Therapeutics (NASDAQ:GEMP) has trended somewhat positive on Saturday, according to Accern. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Gemphire Therapeutics earned a media sentiment score of 0.00 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.2239310384604 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of NASDAQ:GEMP traded down $0.54 during midday trading on Friday, reaching $5.75. The company had a trading volume of 385,506 shares, compared to its average volume of 158,227. The company has a current ratio of 5.57, a quick ratio of 5.57 and a debt-to-equity ratio of 0.37. The firm has a market cap of $89.52 million, a PE ratio of -1.78 and a beta of 4.29. Gemphire Therapeutics has a one year low of $4.75 and a one year high of $21.59.
Get Gemphire Therapeutics alerts:
Gemphire Therapeutics (NASDAQ:GEMP) last issued its quarterly earnings results on Tuesday, May 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.05. equities research analysts forecast that Gemphire Therapeutics will post -2.57 EPS for the current fiscal year.
A number of research firms have recently issued reports on GEMP. ValuEngine upgraded shares of Gemphire Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 7th. Zacks Investment Research lowered shares of Gemphire Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 21st. Finally, Raymond James initiated coverage on shares of Gemphire Therapeutics in a research note on Wednesday, May 16th. They issued an “outperform” rating and a $22.00 price target for the company. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $22.64.
About Gemphire Therapeutics
Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.